CAMBRIDGE, Mass., Nov. 11 /PRNewswire/ -- Quanterix Corporation, the leader in single molecule detection, announced today that Robert Corn, Ph.D. has joined its Scientific Advisory Board (SAB). Dr. Corn is a Professor in the Departments of Chemistry and Biomedical Engineering at the University of California, Irvine. Dr. Corn's primary research areas include the development of new methods for detecting binding of biomolecules to surfaces and chemical modification strategies to control specific and non-specific adsorption of biopolymers to a variety of surfaces.
Dr. David Walt, Scientific Founder of Quanterix and Chair of the SAB, stated, "Dr. Corn is a leader in the field of surface chemistry; his research interests and experience are directly applicable to our Single Molecule Array (SiMoA(TM)) technology. We are eager to draw upon his extensive knowledge and insight as we develop assays and instrumentation that enable unparalleled increases in analytical sensitivity for the detection of proteins implicated in a variety of diseases."
Dr. Corn added, "The novel technology platform being developed by Quanterix will provide medical researchers with a unique tool that allows low abundance biomarkers to be detected in complex biological samples. I am excited to join such a world class Advisory Board and look forward to working with the other members to further advance this promising technology."
Dr. Corn joins SAB members David Walt, Ph.D., Robinson Professor of Chemistry and Howard Hughes Medical Institute Professor, Tufts University (Chairman of the SAB), Larry J. Kricka, D. Phil., Professor of Pathology and Laboratory Medicine at the University of Pennsylvania and Director of the General Chemistry Laboratory at the Hospital of the University of Pennsylvania, J. Michael Ramsey, Ph.D., Minnie N. Goldby Distinguished Professor of Chemistry and Chair at the University of North Carolina at Chapel Hill, and Sunney Xie, Ph.D., Professor of Chemistry at Harvard University.
Quanterix is developing a revolutionary Single Molecule Array (SiMoA(TM)) technology that allows the behavior of thousands of individual molecules to be observed simultaneously, rather than an ensemble average of many molecules as with existing technologies. Quanterix's platform will bring an unprecedented level of sensitivity, precision, and assay robustness to clinical diagnostics, drug development, and life science research. The first application that Quanterix is pursuing with the SiMoA(TM) technology is the detection and quantification of proteins present in blood and other body fluids at very low, previously undetectable, concentrations. Diagnostic assays targeting proteins that have been implicated in a variety of human diseases, including cancer, chronic inflammatory disease and cardiovascular disease are under development. Quanterix is a privately held company located in Cambridge, Massachusetts and is backed by leading life science investors including ARCH Venture Partners, Bain Capital Ventures, and Flagship Ventures. For additional information, please visit http://www.quanterix.com.